The Board of Directors of the Company on 16 December 2025 has approved the conversion of 3,71,000 fully convertible warrants into 3,71,000 Equity shares of face value of Rs. 10/- each, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Terce Laboratories announced that its Board has approved the conversion of 3,71,000 fully convertible warrants into an equal number of equity shares of face value ₹10 each at an issue price of ₹37.70 per share. The warrants were exercised by Mr. Aalap Natubhai Prajapati, the company's Promoter and Managing Director, under a preferential allotment originally made on 1 July 2024. The company received the balance consideration of about ₹1.05 crore on 16 December 2025, taking total consideration to roughly ₹1.40 crore. As a result, the promoter group's shareholding has risen from 37.03% to 40.03%, and the company's paid-up equity capital has increased from 74,20,300 shares to 77,91,300 shares.
This is a promoter-led equity infusion with no new external investor, which signals the promoter's continued commitment but also results in dilution for existing public shareholders. The stock may see mild dilution pressure, though the promoter's increased stake is generally viewed as a confidence signal.